NasdaqGS:CYTKBiotechs
Cytokinetics Faces Governance Inquiry As Aficamten Delay Meets Undervalued Stock
Investors are facing fresh scrutiny of Cytokinetics (NasdaqGS:CYTK) as a formal investigation looks at potential fiduciary duty breaches by certain directors and officers.
The inquiry focuses on an alleged omission of a required Risk Evaluation and Mitigation Strategy from the New Drug Application for aficamten.
This omission reportedly led to a three month delay in FDA approval, raising questions about governance, disclosure practices and regulatory oversight at the company.
Cytokinetics,...